Literature DB >> 27965522

Corrigendum to "Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease".

Bryan Phillips-Farfán1, Karla Carvajal1, Edgar Alejandro Medina-Torres2, Sara Elva Espinosa-Padilla2, Gemma Fabrias3, Luz Camacho1.   

Abstract

[This corrects the article DOI: 10.1155/2016/9890141.].

Entities:  

Year:  2016        PMID: 27965522      PMCID: PMC5124652          DOI: 10.1155/2016/7267956

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


In the article titled “Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease” [1], reference [28] was incorrectly added as follows:It should be replaced with the following reference: “Y. Chen, S.-C. Xu, and R.-D. Duan, ‘Mevalonate inhibits acid sphingomyelinase activity, increases sphingomyelin levels and inhibits cell proliferation of HepG2 and Caco-2 cells,' Lipids in Health and Disease, vol. 14, no. 1, article 130, 2015.” “Chen Y, et al. Enhanced colonic tumorigenesis in alkaline sphingomyelinase (NPP7) knockout mice. Mol Cancer Ther, 14:1, 259-67, 2015.”
  1 in total

Review 1.  Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease.

Authors:  Phillips-Farfán Bryan; Carvajal Karla; Medina-Torres Edgar Alejandro; Espinosa-Padilla Sara Elva; Fabrias Gemma; Camacho Luz
Journal:  Mediators Inflamm       Date:  2016-08-30       Impact factor: 4.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.